Overview

Etoricoxib Prescribing Patterns and Adverse Events of Interest in Primary Care in the United Kingdom (MK-0663-162 AM1)

Status:
Completed
Trial end date:
2015-03-01
Target enrollment:
0
Participant gender:
All
Summary
This postmarketing study was conducted to describe prescribing patterns for etoricoxib (ARCOXIA®) in General Practice and describe the incidence of selected adverse events recorded in the United Kingdom (UK) Medicines and Health Care Products Regulatory Agency (MHRA) General Practice Research Database (GPRD).
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Merck Sharp & Dohme Corp.
Treatments:
Etoricoxib
Criteria
Inclusion Criteria:

- All patients in the MHRA's Full Feature GPRD (FF-GPRD) who have at least one
electronic outpatient prescription record for etoricoxib issued by a General
Practitioner during the period (April 1, 2002 to December 31, 2015) at the date of
query execution against the FF-GPRD data warehouse.

Exclusion Criteria:

- Not registered in a GPRD-contributing practice that had continuously

collected data deemed to be 'up-to-standard' for research purposes from 1 April 2002
through to 31 December 2015.

- Never registered as a permanent patient of a General Practitioner in the practice

- Registration details were not acceptable (i.e. incomplete data or logically
implausible dates)

- Not registered with a General Practitioner for at least 365 days before the date that
the patient's first etoricoxib prescription was recorded in the GPRD